- Home
- ASND vs GH Comparison
ASND vs GH Comparison
Compare ASND & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | GH |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 13.3B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASND | GH |
|---|---|---|
| Price | $232.30 | $94.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 20 |
| Target Price | ★ $277.13 | $117.80 |
| AVG Volume (30 Days) | 694.9K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $98.99 | $29.73 |
| Revenue Next Year | $41.45 | $27.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $124.06 | $34.91 |
| 52 Week High | $242.00 | $120.74 |
Technical Indicators
Market Signals| Indicator | ASND | GH |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 36.72 |
| Support Level | $190.49 | $54.39 |
| Resistance Level | $242.00 | $115.77 |
| Average True Range (ATR) | 9.59 | 6.12 |
| MACD | 0.44 | -1.26 |
| Stochastic Oscillator | 81.29 | 9.73 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.